Tiziana Life Sciences Plc - Company Profile
Powered by 
All the data and insights you need on Tiziana Life Sciences Plc in one report.
$295
- Save hours of research time and resources with
our up-to-date Tiziana Life Sciences Plc Strategy Report
- Understand Tiziana Life Sciences Plc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Tiziana Life Sciences Ltd (Tiziana), formerly Tiziana Life Sciences Plc, is a clinical-stage biotechnology company that discovers and develops drugs to treat inflammatory diseases and cancers. Its lead product candidate, Milciclib (TZLS-201), intended for the treatment of thymic carcinoma. The company's other clinical programs includes Foralumab (TZLS-401), a human engineered anti-human CD3 antibody intended for the treatment of Crohn’s disease and Nonalcoholic steatohepatitis. The company’s preclinical stage candidates include anti-IL6R (TZLS-501), a fully human anti-IL-6R monoclonal antibody targeting the interleukin-6 receptor. Tiziana is headquartered in London, the UK.
Headquarters
United Kingdom
Address
14/15 Conduit Street, Hamilton, South Lanarkshire, W1S2XJ
Website
www.tizianalifesciences.com
Telephone
44 20 74952379
No of Employees
9
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
TLSA (NASD)
EPS
XYZ
Net Income (2022)
XYZ
34.2%
(2022 vs 2021)
Market Cap*
$46.5M
* As of and is in US$
Tiziana Life Sciences Plc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline: |
| Clinical Programmes |
| Milciclib - Thymic Carcinoma |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Tiziana Life Sciences Plc | BioNTech SE | Iovance Biotherapeutics Inc | Celgene Corp | Juno Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United Kingdom | Germany | United States of America | United States of America | United States of America |
| City | Hamilton | Mainz | San Carlos | Summit | Seattle |
| State/Province | South Lanarkshire | Nordrhein-Westfalen | California | New Jersey | Washington |
| No. of Employees | 9 | 4,530 | 557 | - | 533 |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Gabriele Marco Antonio Cerrone | Chairman; Chief Executive Officer - Acting | Executive Board | 2022 | 51 |
| Keeren Shah | Chief Financial Officer | Senior Management | 2020 | - |
| Matthew W. Davis, MD | Chief Operating Officer; Chief Medical Officer | Senior Management | 2023 | - |
| William A. Clementi | Chief Development Officer | Senior Management | 2023 | - |
| Vaseem A. Palejwala, Ph.D. | Senior Director-Clinical Operations | Senior Management | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward